Pharma Wellness

Metabolic diseases are becoming increasingly prevalent and have a major impact on public health worldwide. Major metabolic diseases include metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Insulin resistance is a key component for metabolic syndrome and metabolic diseases such as type 2 diabetes and NAFLD with metabolic syndrome patients are diagnosed when they have at least three of the following risk factors: abdominal obesity, hypertriglyceridemia, elevated blood pressure, low high-density lipoprotein (HDL) cholesterol, or glucose intolerance. Type 2 diabetes afflicts close to 200 million worldwide and type 2 diabetic patients have obesity-related metabolic syndrome. Diabetes is already the leading cause of blindness, end-stage liver disease, and end-stage renal disease. Likewise, NAFLD is the most common chronic liver disease and affects up to one-third of the adult population. A large portion of patients with NAFLD display typical features of metabolic syndrome including abdominal obesity, dyslipidemia, hypertension, insulin resistance, or type 2 diabetes. Developing adequate therapeutic and preventive measures for these multifactorial metabolic diseases has so far been challenging. Indeed, due to the complex pathophysiology, the current therapeutic approaches to treat metabolic syndrome, type 2 diabetes, and NAFLD need multiple treatments regulating lipid and glucose homeostasis as well as blood pressure control.

Mitochondrial Abnormalities is the root cause of many diseases that are bewildering in their variety and complexity. Mitochondrial disease is an inherited chronic illness that can be present at birth or develop later in life. It causes debilitating physical, developmental, and cognitive disabilities with symptoms including poor growth; loss of muscle coordination; muscle weakness and pain; seizures; vision and/or hearing loss; gastrointestinal issues; learning disabilities; and organ failure. It is estimated that 1 in 4,000 people has Mitochondrial abnormalities. It’s progressive and there is no cure.

It is imperative to understand the sensitivity of this burden and address it with coherence. Bion Therapeutics is the 1st company in India to address the medical gap in the management of this therapy with an absolute product basket addressing disorders like Neurodegenerative Disorders, Movement Disorder, Muscle Cramps/Pain, Chronic Fatigue Syndrome, Cardiac Myopathy, Non-alcoholic Fatty Liver Disease, Male Infertility etc. with an aim of remission or even curing the illnesses.